Voyager Therapeutics, Inc. (NASDAQ:VYGR)‘s stock had its “buy” rating restated by Cowen and Company in a research note issued to investors on Tuesday.

The analysts wrote, “Tonight we hosted a dinner with VYGR just after the announcement that SNY did not.””

Several other equities research analysts have also recently issued reports on VYGR. Canaccord Genuity started coverage on shares of Voyager Therapeutics in a report on Friday. They issued a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Chardan Capital restated a “hold” rating on shares of Voyager Therapeutics in a report on Sunday, September 10th. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Finally, Stifel Nicolaus started coverage on shares of Voyager Therapeutics in a report on Friday, July 28th. They issued a “buy” rating and a $20.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.89.

Shares of Voyager Therapeutics (VYGR) traded down 6.78% during trading on Tuesday, hitting $21.19. The stock had a trading volume of 501,725 shares. The stock has a 50 day moving average of $19.97 and a 200 day moving average of $12.28. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99. The firm’s market cap is $570.07 million.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative net margin of 712.22% and a negative return on equity of 46.15%. The firm had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million. On average, equities analysts anticipate that Voyager Therapeutics will post ($2.89) EPS for the current year.

WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/31/cowen-and-company-reaffirms-buy-rating-for-voyager-therapeutics-inc-vygr.html.

In other news, insider Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the transaction, the insider now owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 32,940 shares of company stock worth $490,092 in the last quarter. Corporate insiders own 8.00% of the company’s stock.

Several institutional investors have recently modified their holdings of VYGR. DAFNA Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 187.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after acquiring an additional 133,488 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Voyager Therapeutics by 232.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock worth $879,000 after acquiring an additional 68,574 shares during the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Voyager Therapeutics during the 3rd quarter worth $1,122,000. HarbourVest Partners LLC purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth $400,000. Finally, Northern Trust Corp boosted its stake in shares of Voyager Therapeutics by 26.8% during the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after acquiring an additional 28,222 shares during the last quarter. Institutional investors and hedge funds own 40.72% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.